awmsg logo



tacrolimus (Envarsus®)


Reference No. 2586

Publication date:
02/09/2015


Appraisal information

tacrolimus (Envarsus®) 0.75 mg prolonged-release tablet
tacrolimus (Envarsus®) 1 mg prolonged-release tablet
tacrolimus (Envarsus®) 4 mg prolonged-release tablet


Company: Chiesi Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/06/2015
AWMSG meeting date: 15/07/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2315
Ministerial ratification: 27/08/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tacrolimus (Envarsus®) is recommended as an option for use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download